Of note, PY109, an AHR agonist that has physiochemical drug-likeness properties, ameliorates DSS-induced colitis in mice by promoting the expansion of ILC3s and γδ T cells and expression of IL-22 and IL-17 (143). The gene discussed is IL17A; the disease is colitis.